Showing results (161-170 of 192) with videos related to
Sort By:
Pageof 20
Genome Medicine|May 11, 2021
Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysisSunny Z Wu, Daniel L Roden, Ghamdan Al-Eryani, et al.JAMA|April 20, 2016
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaAntoni Ribas, Omid Hamid, Adil Daud, et al.Journal of Cancer Research and Clinical Oncology|December 7, 2016
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanomaThomas M Atkinson, Jennifer L Hay, Alexander Shoushtari, et al.The New England Journal of Medicine|September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancerAslı D Munzur, Cameron Herberts, Edmond M Kwan, et al.The Lancet. Oncology|April 2, 2026
[<sup>177</sup>Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 studyShahneen Sandhu, Anthony M Joshua, Louise Emmett, et al.Journal for Immunotherapy of Cancer|April 13, 2022
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trialCharu Aggarwal, Amy Prawira, Scott Antonia, et al.The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.NPJ Precision Oncology|May 7, 2026
A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseasesSarah Childs, David Ma, Elizabeth Houghton, et al.Ebiomedicine|October 17, 2021
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinaseHui-Ming Lin, Blossom Mak, Nicole Yeung, et al.Pageof 20